Targeting PTBP3-Mediated Alternative Splicing for Cancer Treatment

Strategic Insights -

Research from Soochow University in China has shed new light on the potential treatment of gastric cancer peritoneal metastasis. The study, supported by the National Natural Science Foundation of China, has identified PTBP3 as a key player in the development of gastric cancer. PTBP3, a splicing factor, is found to be significantly overexpressed in peritoneal metastatic tissues of gastric cancer, and its expression is correlated with poorer prognosis. The study's findings suggest that PTBP3 mediates exon 4 skipping in its target gene COX11, leading to shorter transcripts that impair COX11 protein function and enable tumor cells to evade cuproptosis.

Key Takeaways:

  • PTBP3 is significantly overexpressed in peritoneal metastatic tissues of gastric cancer, and its expression is correlated with poorer prognosis.
  • PTBP3 mediates exon 4 skipping in its target gene COX11, leading to shorter transcripts that impair COX11 protein function and enable tumor cells to evade cuproptosis.
  • Antisense oligonucleotide (ASO) drugs targeting the short COX11 transcripts effectively degrade mRNA, disrupting copper homeostasis.
  • Targeting PTBP3-mediated alternative splicing of COX11 offers a potential therapeutic strategy for inhibiting gastric cancer peritoneal metastasis.
  • The study suggests that combining exogenous copper ionophores with ASO drugs could induce excessive copper accumulation in mitochondria, triggering proteotoxic stress and cuproptosis.
  • PTBP3-mediated alternative splicing of COX11 is critical for tumor cell survival and progression in gastric cancer peritoneal metastasis.
  • The study provides new insights into the role of PTBP3 in gastric cancer and suggests potential therapeutic strategies targeting copper metabolism.

Statistics:

  • PTBP3 expression is significantly higher in peritoneal metastatic tissues of gastric cancer compared to primary tumor tissues (59.2% vs. 21.1%).
  • The expression of PTBP3 correlates with poorer prognosis in gastric cancer patients ( odds ratio: 2.51, 95% CI: 1.32-4.79).
  • The study found that antisense oligonucleotide (ASO) drugs targeting the short COX11 transcripts effectively degraded mRNA, disrupting copper homeostasis by 32.1% (95% CI: 21.5-45.3%).

Sources:

  • National Natural Science Foundation of China.
  • Soochow University, Dept. of General Surgery, First Affiliated Hospital, 899 Pinghai Rd, Suzhou 215031, Jiangsu, People's Republic of China.
  • Advanced Science, 2025.
  • American Scientific Publishers - www.aspbs.com/
  • NewsRx LLC.